You are here: Home » Companies » News
Business Standard

Biocon partners with Teleradiology Solutions

Press Trust of India  |  Bangalore 

Kiran Mazumdar Shaw

Leading biotechnology company Biocon has entered into an agreement with Teleradiology Solutions to provide teleradiology reporting services to Clinigene, Biocon's clinical research arm.

Teleradiology Solutions offers pharmaceutical vendors, clinical research organisations and biotechnology organisations the opportunity to shorten their development cycles by using its clinical trials radiology reporting service, a company press release said.

Teleradiology Solutions MD and Chief Radiologist Dr Arjun Kalyanpur said delays in the drug development cycle can be an issue of concern for pharmaceutical and biotechnology firms involved in drug development and R&D. These are related in part to delays in reporting of radiologic scans performed to confirm that the patient has responded positively to the drug being evaluated in the clinical trial, he said.

"The delays are in turn related to the worldwide shortage of radiologists, estimated to be as high as 20 per cent in some studies. We are happy to partner with Biocon and offer our services to ensure timely execution and quality evaluation for clinical trials in radiology," he said.

The organisation offers reporting by radiologists experienced in RECIST (Response Evaluation Criteria In Solid Tumors) and WHO (World Health Organisation) measurement criteria, he said.

According to Biocon Ltd Chairman & Managing Director Kiran Mazumdar-Shaw, "To achieve our main objective, accelerating clinical research, we leverage on an adept mix of technology, experience and personal traits. Keeping in line with our mission, Teleradiology Solutions, given their impressive track record, was the partner of choice to meet our complex image analysis requirements."

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, September 15 2010. 17:18 IST